Insider Buying: DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) CEO Acquires 60,900 Shares of Stock

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) CEO Saiid Zarrabian bought 60,900 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $0.82 per share, for a total transaction of $49,938.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

DelMar Pharmaceuticals, Inc. (DMPI) opened at $0.92 on Monday. DelMar Pharmaceuticals, Inc. has a one year low of $0.78 and a one year high of $5.39.

DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). equities analysts forecast that DelMar Pharmaceuticals, Inc. will post -0.6 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the stock. Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th. HC Wainwright set a $12.00 price objective on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 29th. Finally, Maxim Group reiterated a “hold” rating on shares of DelMar Pharmaceuticals in a research report on Monday, September 11th.

Institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP bought a new position in DelMar Pharmaceuticals in the third quarter valued at approximately $306,000. Sabby Management LLC bought a new position in DelMar Pharmaceuticals in the second quarter valued at approximately $1,484,000. Finally, Franklin Resources Inc. bought a new position in DelMar Pharmaceuticals in the second quarter valued at approximately $2,477,000. 16.91% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Insider Buying: DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) CEO Acquires 60,900 Shares of Stock” was originally reported by Week Herald and is owned by of Week Herald. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://weekherald.com/2017/12/04/delmar-pharmaceuticals-inc-dmpi-ceo-saiid-zarrabian-acquires-60900-shares.html.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Insider Buying and Selling by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply